TGTX - TG Therapeutics: BRIUMVI Development Could Lead To Great Results

2024-04-12 18:17:47 ET

Summary

• TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023, with positive market feedback and significant revenue.
• The company has strong barriers to entry and patent protection for BRIUMVI, allowing for potential growth in 2024 and 2025.
• Hedge funds have started reinvesting in TG Therapeutics, indicating confidence in the company's future prospects.

TG Therapeutics Inc. ( TGTX ), saw its multiple sclerosis drug BRIUMVI approved by the FDA at the end of 2022 and the launch began in January 2023. There was no shortage of results in the same year, and new partnerships were consolidated for marketing outside the US. Based on the results achieved in 2023, the revenue and earnings growth hypotheses are very encouraging for 2024, and although, to date, the share price may be overestimated, if future growth hypotheses are realized, an investment today could bring excellent results.

Regarding competition, it should be noted that some barriers to entry are evident and could protect the product by allowing significant growth in 2024 and 2025. Hedge funds have begun to reinvest in TGTX as they did in 2020 and 2021....

For further details see: